Lineage Cell Therapeutics (LCTX) Enterprise Value (2010 - 2026)

Lineage Cell Therapeutics' Enterprise Value history runs 17 years deep, the most recent figure standing at -$63.9 million for Q1 2026.

• In Q1 2026, Enterprise Value fell 29.67% year-over-year to -$63.9 million; the TTM figure through Mar 2026 stood at -$63.9 million (down 29.67% YoY), while the FY2025 annual figure was -$62.2 million, down 39.99% from the prior year.
• Enterprise Value for Q1 2026 stood at -$63.9 million, down from -$62.2 million in the prior quarter.
• The five-year high for Enterprise Value was -$31.4 million in Q4 2023, with the low at -$81.3 million in Q1 2022.
• The 5-year median for Enterprise Value is -$47.3 million (2023), against an average of -$51.0 million.
• The sharpest annual moves came in 2023 and 2024: Enterprise Value jumped 47.06% in 2023, then tumbled 41.5% in 2024.
• Lineage Cell Therapeutics' Enterprise Value stood at -$59.3 million in 2022, then surged by 47.06% to -$31.4 million in 2023, then sank by 41.5% to -$44.4 million in 2024, then slumped by 39.99% to -$62.2 million in 2025, then slipped by 2.8% to -$63.9 million in 2026.
• Business Quant data shows LCTX's Enterprise Value at -$63.9 million in Q1 2026, -$62.2 million in Q4 2025, and -$33.5 million in Q3 2025.